Immutep to receive $7.4m from GSK


GSK licensed the GSK2831781 drug from Immutep in 2010, with Immutep eligible for up to $118 million in milestone payments as well as royalties if the drug is commercialised.

At 1235 AEST, Immutep shares were up 13.6 per cent to a three-month high of 2.5 cents.